Designing the Safe Reopening of US Towns Through High-Resolution Agent-Based Modeling

Truszkowska, Agnieszka; Thakore, Malav; Zino, Lorenzo; Butail, Sachit; Caroppo, Emanuele; Jiang, Zhong-Ping; Rizzo, Alessandro; Porfiri, Maurizio

Published in:
Advanced theory and simulations

DOI:
10.1002/adts.202100157

ADVANCED THEORY AND SIMULATIONS
www.advtheorysimul.com

Designing the Safe Reopening of US Towns Through High-Resolution Agent-Based Modeling

*Agnieszka Truszkowska, Malav Thakore, Lorenzo Zino, Sachit Butail, Emanuele Caroppo, Zhong-Ping Jiang, Alessandro Rizzo, and Maurizio Porfiri**

As COVID-19 vaccine is being rolled out in the US, public health authorities are gradually reopening the economy. To date, there is no consensus on a common approach among local authorities. Here, a high-resolution agent-based model is proposed to examine the interplay between the increased immunity afforded by the vaccine roll-out and the transmission risks associated with reopening efforts. The model faithfully reproduces the demographics, spatial layout, and mobility patterns of the town of New Rochelle, NY — representative of the urban fabric of the US. Model predictions warrant caution in the reopening under the current rate at which people are being vaccinated, whereby increasing access to social gatherings in leisure locations and households at a 1% daily rate can lead to a 28% increase in the fatality rate within the next three months. The vaccine roll-out plays a crucial role on the safety of reopening: doubling the current vaccination rate is predicted to be sufficient for safe, rapid reopening.

1. Introduction

One year after the global outbreak of COVID-19, the World is finally witnessing the roll-out of vaccination campaigns. As more people are becoming immune to the disease, policy makers are gradually devising the uplifting of restrictive policies. With over 2.4% of the World and almost 24% of the US population fully vaccinated as of mid-April 2021,[1] governments are increasingly seeking to resume normal activities in all segments of life. Many US states are actively reopening all their non-essential services and reducing the strictness of some of their public health measures. The epidemiological effects of these reopening efforts are still under debate, with diverging opinions across political aisles and too few empirical observations to draw statistically-grounded claims.[2–4] While it is generally accepted that the ongoing vaccine roll-out will gradually reduce the spread, the extent to which it can afford safe reopening of the economy remains elusive. There is a pressing need for scientifically-backed approaches that can inform policy-making to relaunch the economy and resume normalcy, while preventing resurgent COVID-19 waves.

Dr. A. Truszkowska, Prof. M. Porfiri
Center for Urban Science and Progress
Tandon School of Engineering
New York University
370 Jay Street, Brooklyn, NY 11201, USA
E-mail: mporfiri@nyu.edu
Dr. A. Truszkowska, Prof. M. Porfiri
Department of Mechanical and Aerospace Engineering
Tandon School of Engineering
New York University
Six MetroTech Center, Brooklyn, NY 11201, USA
M. Thakore, Prof. S. Butail
Department of Mechanical Engineering
Northern Illinois University
DeKalb, IL 60115, USA
Dr. L. Zino
Faculty of Science and Engineering
University of Groningen
Nijenborgh 4, Groningen 9747 AG, The Netherlands
Prof. E. Caroppo
Department of Mental Health
Local Health Unit ROMA 2
Rome 00159, Italy
Prof. E. Caroppo
University Research Center He.R.A.
Università Cattolica del Sacro Cuore
Rome 00168, Italy
Prof. Z.-P. Jiang
Department of Electrical and Computer Engineering
Tandon School of Engineering
New York University
370 Jay Street, Brooklyn, NY 11201, USA
Prof. A. Rizzo
Department of Electronics and Telecommunications
Politecnico di Torino
Turin 10129, Italy
Prof. A. Rizzo
Office of Innovation
Tandon School of Engineering
New York University
Six MetroTech Center, Brooklyn, NY 11201, USA
Prof. M. Porfiri
Department of Biomedical Engineering
Tandon School of Engineering
New York University
Six MetroTech Center, Brooklyn, NY 11201, USA

The ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/adts.202100157

DOI: 10.1002/adts.202100157

Since the inception of the worldwide COVID-19 pandemic in January 2020, mathematical models have emerged as powerful tools to combat its spread.[5–7] In the first phase of the pandemic, models have been largely adopted to conduct what-if analyses on the effect of nonpharmaceutical interventions (NPIs) for the containment of the spread,[8–12] also considering their socio-economic and psychological impact.[13–15] More recently, models are gaining traction as decision support systems to design efficient vaccination campaigns.[16–24] Effective vaccine roll-out strategies are the solution of complex optimization problems, due to limited availability of vaccines, differential effectiveness and adverse effects across age strata and fragility profiles, time constraints on double-dose administration, and distribution issues.[16,17] Ongoing efforts have quantitatively addressed several aspects of vaccination campaigns. In Shen et al.,[18] the admissible level of relaxation of NPIs has been evaluated as a function of vaccination coverage and effectiveness of the vaccine. Giordano et al.[19] and Moore et al.[20] have highlighted the importance of maintaining NPIs during the early stages of vaccination roll-outs in Italy and the United Kingdom, respectively. The problem of coordinating the early-stage of vaccination campaigns and intervention policies has also been investigated in other studies,[21–24] focusing on the spread of virus variants that are potentially resistant to the vaccine.

Overall, these modeling efforts provide important insight into several aspects of vaccine roll-outs; however, they are based on coarse-grained assumptions that may not capture the complexity of the spreading dynamics. Whether they employ compartments[18,19,21,23,24] or meta-populations,[20,22] these models cannot resolve the richness of the geographical distribution of the population, the different epidemiological risk factors associated with the locations where people can come into contact, and the wide range of mobility patterns, among other factors. Agent-based models (ABMs) represent a powerful alternative to compartmental and meta-population models, one that is able to describe spreading dynamics with the accuracy and detail that is needed to support the assessment of different intervention strategies.[25–27] In particular, through ABMs, it is possible to accurately simulate COVID-19 spread over entire towns.[28]

Here, we propose a high-resolution ABM of a medium-sized US town (New Rochelle, NY), for which we systematically examine the interplay between the risks associated with reopening efforts and the increased immunity provided by the vaccine roll-out. We specifically seek to understand what should be the speed of the vaccination campaign that would afford safe reopening of the economy. The model operates at a full population resolution, so that one agent in the model corresponds to one individual within the population of New Rochelle. Using publicly available data, the model faithfully reproduces the town demographics, the spatial layout and use of every town building, and the mobility patterns of the entire population.

2. Results

2.1. High-Resolution COVID-19 ABM with Human Mobility

Our computational framework consisted of two elements: a database of a US town and a highly granular agent-based model (ABM) of COVID-19 with human mobility. The database reproduced the town of New Rochelle, NY, where one of the first US COVID-19 outbreaks took place.[29] New Rochelle has a population of 79 205 inhabitants[30] and a representative structure of many urban areas in the US.[31] The population was recreated using US Census statistics,[30] accounting for realistic age distribution, household and family structure, and occupational characteristics of the town residents (the model distinguishes hospital, retirement home, and school employees from all other occupations). US Census data[30] was also used for the assignment of workplaces for the agents, encompassing work from home, in the town, or in nearby locations (including the New York City boroughs, upstate New York, and Connecticut). Utilizing data from OpenStreetMap,[32] Google Maps,[33] and Safegraph,[34] we assembled a database including every building in the town, residential or public, as detailed in Section 4.

The proposed ABM is a highly granular model that simulated COVID-19 spread to afford "what-if" analyses on public health measures, whose backbone was first introduced in our previous work.[28] Every individual in the town is represented by an agent, and the spread of COVID-19 is modeled by explicitly considering their households, lifestyles, schools, and workplaces. The model incorporates known stages of the COVID-19 disease progression, that is, the pre-symptomatic, the symptomatic phase, and the possibility of never developing symptoms. The two possible outcomes of the disease, recovery and death, are included in the ABM. Over the duration of the disease, agents can be tested for COVID-19, quarantined, hospitalized, and treated in an intensive care unit. The model can also simulate vaccination campaigns and a wide variety of NPIs, including school closures, lockdowns, and social distancing, and, indirectly, the use of PPE.

Toward examining the role of reopening efforts on COVID-19 spread, we extended our previous effort[28] to include realistic human mobility patterns; the new components are summarized in **Figure 1**, see Section 4 for more details. Specifically, the improved framework incorporates the following mobility patterns: i) agents can work outside the town; ii) agents can travel to work through five different modes of transportation; iii) agents can spend time in leisure locations, such as cinemas, theaters, and restaurants; and iv) agents can visit each other at their households to socialize. Agents travel to work via five transit modes identified in the US Census: car, carpool, public transit, walking, and others, such as cycling. COVID-19 spread was only modeled in carpools and public transit.

We conducted a series of simulations to assess the interplay between the vaccine roll-out and the reopening of the economy on the spread of COVID-19. The spread of COVID-19 was simulated by initializing the ABM with officially reported, county-level statistics, including those on the number of undetected and asymptomatic cases (in total 187 active cases). The vaccine roll-out was modeled as a constant fraction of the town population being immunized each day. Reopening efforts were modeled by increasing the frequency at which agents visited leisure locations and each other (see Section 4). Concurrently, the infection risk at leisure locations was also gradually increased to simulate eased restrictions at those places. To quantify the mediating role of testing, we performed these simulations at three different efficacies: i) average testing as calibrated in our previous work[28] for the Spring and early Summer of 2020 (64% of the symptomatic and 44% of the asymptomatic are detected);



Figure 1. Schematic outline of the model and human mobility elements. The model simulates all the residents of New Rochelle, NY. In addition to residences, hospitals, workplaces, and schools, COVID-19 can spread during transit, in leisure locations, and when socializing in private. A portion of the population works outside of town, in nearby areas that are also experiencing COVID-19 spreading.

ii) perfect testing, where all but those who were asymptomatic at the beginning of the simulations undergo testing; and iii) intermediate testing, between i) and ii) (82% of the symptomatic and 72% of the asymptomatic are detected). Across all levels, we included a 95% confidence in the test accuracy, thereby leading to false negatives even for perfect testing.

As expected, the testing efficacy itself has a critical effect on the number of infections and deaths with an approximately tenfold increase in each value as efficacy goes from perfect to low. More worryingly, however, for low testing and the current vaccination rate, we observed a 28% increase in fatality rate as the reopening rate rises by only 1% per day.

2.2. Current Vaccination Rates Warrant Caution in Reopening Efforts

When simulated for 3 months with a recent vaccination rate of 0.57% population per day,[1] **Figure 2** reveals a clear influence of the reopening rate on the number of infections across all levels of testing efficacies. In all scenarios, the total number of infected visibly increases with the reopening rate, eventually plateauing to a maximum value.

In particular, as reopening rates exceed 0.1% per day, the total number of infected rises regardless of the efficacy of testing. To put this claim in context, from SafeGraph data,[34] we estimated the reopening rate in NY as of mid-April 2021 to be approximately 0.28% per day, see Section 4. As the reopening rates increase beyond about 3% per day, the number of infected levels out to a maximum value. With respect to the number of deaths, we registered a similar trend of a steep initial rise followed by a plateau for both low and moderate tracing; for perfect tracing, the number of deaths has a marginal dependence on the reopening rate.

2.3. Faster, yet Safe Reopening Is Possible with More Daily Vaccinations

To quantify the extent to which faster vaccine roll-out can mitigate the adverse epidemiological effects of reopening, we performed a second, more extensive, study. Specifically, we compared the cumulative number of infections and the death toll for a range of possible vaccination and reopening rates. Results, shown in **Figure 3**, indicate that, while aggressive vaccination campaigns can offset ambitious reopening efforts, low vaccination rates can easily degenerate into dramatic growths in number of infections and fatalities as reopening rates increase.

Specifically, we found that: a) high vaccination rates, above 1% population per day, can bring down infections and fatalities dramatically to less than 10, at even the fastest reopening rate of 5% per day; b) the reopening rate has a secondary effect on the numbers of infections and deaths when vaccination rates exceed 0.2%, as evidenced by near horizontal contour lines within that region of the heatmaps; and c) high reopening rates, above 1%



Figure 2. Impact of the reopening rate on the spread of COVID-19 over a three-month duration. The three different testing efficacies—low, moderate, and perfect—correspond to different detection levels across asymptomatic and symptomatic individuals. Note that the maximum value along the ordinate is different for each level of testing. The bottom and top edges of the box plots mark the 25th and 75th percentiles, the solid lines represent the median, and the whiskers span entire, outlier-free dataset; outliers are denoted by '+' symbols.



Figure 3. Interplay between vaccine roll-out and reopening rates, in the form of 2D heatmaps. The colorbar on the right of each heatmap shows the total number of infected, and deaths are reported as a function of varying vaccination and reopening rates. Contour lines are also plotted for clarity.

per day, can lead to a dramatic increase in the numbers of infections and deaths if not supported by an aggressive vaccination campaign. Overall, these plots point at a rich, nonlinear interplay between vaccination and reopening rates on COVID-19 spread, upon which we recommend doubling the current rate of vaccination to at least 1% per day to afford safe reopening.

Comparing across different levels of testing, we noted, once again, the crucial role that efficacious testing plays in containing the number of infections and deaths. In particular, while the general implications of high vaccination rates and low reopening rates remain the same, the actual numbers scale down by a factor of ten as the efficacy of testing drops from perfect to low, confirming the critical role of capillary and continuous testing of the population.

3. Discussion and Conclusion

In this work, we examined the complex interplay between the transmission risks brought about by ongoing reopening efforts and increased immunity offered by vaccine roll-out on the spread of COVID-19 in an urban setting. We designed and implemented a highly granular ABM, by extending the effort of Truszkowska et al.,[28] to account for population mobility, non-essential leisure activities and gatherings in households, progressive reopening efforts, and vaccination campaigns. The model was calibrated on New Rochelle, NY, a medium-sized town representative of a vast class of US urban areas. We explored both current and hypothetical vaccination campaigns, for three realistic scenarios of testing efficacy.

Our results indicate that as of April 2021 (the time at which this study is being performed), the vaccination rate of 0.57% population per day[1] in New Rochelle, NY, can only support a careful reopening. With this rate of vaccine roll-out, reopening efforts would always lead to a rise in the numbers of infected individuals and casualties; not even under a perfect testing where every infected individual is traced and isolated, it would be possible to halt COVID-19 spread. The concurrent reopening rate of 0.28% per day could lead to a number of deaths as high as one hundred and fifty, a mortality rate similar to the "first wave". These findings are in agreement with other studies that have shown that the relaxation of NPIs always causes increases of COVID-19 infections and deaths. Shen et al.,[18] established that under current levels of vaccine effectiveness and coverage in the US, moderate NPIs, in the form of partial use of PPEs, are required to prevent further outbreaks. Likewise, Giordano et al.[19] demonstrated that the current vaccine roll-out in Italy does not support uplifting of NPIs, without a substantial rise of infections and casualties. Many other research efforts have confirmed that rapid lifting of NPIs would have dramatic consequences on the spread of COVID-19, notwithstanding the current vaccine roll-out.[20–24] In general, the scientific community has reached consensus on the need of extreme caution in reopening the economy, in support to concerns of about half of the US population who fear that the current status of the vaccination campaign may not be conducive to return to normalcy in the near future.[2]

We then conducted a what-if analysis for different vaccination rates, toward determining whether safe reopening could be supported by a faster vaccine roll-out than the current one. We registered the existence of a trade-off between the vaccination and reopening rates with respect to the numbers of infections and casualties. While for low vaccination rates we observed a dramatic growth in infection and death counts as the reopening rate increases, cases and deaths settle around constant values for sufficiently high vaccination rates. Our findings suggest that doubling the current vaccination rate to at least 1% population per day could support safe and fast comeback to normalcy, whereby reopening could be accelerated without risking another COVID-19 outbreak. It is tenable that this phenomenon is related to the reduction of the effective reproduction number in response to vaccine roll-out above a critical rate, which has been observed in simplified compartmental models.[35]

Last, our study echoes experts in highlighting the importance of efficacious testing for safe reopening, even in the current phase of the pandemic when mass vaccination is ongoing.[36,37] The United Kingdom, for example, is offering free testing to each person twice a week, starting from April 9, 2021.[38] Specifically, we assessed the implications of three increasingly efficacious testing scenarios, from the lowest one corresponding to the first wave (Summer 2020) and the best one to ideal conditions. While the trends regarding the interplay between vaccination and reopening rates do not qualitatively change with testing, the sheer toll of the epidemic increases dramatically for low levels of testing efficacy. Notably, we registered that perfect testing may reduce casualties by one order of magnitude with respect to the worst-case scenario, for most of the combinations of vaccination and reopening rates.

Our findings are consistent with claims drawn by other studies in the literature,[18–24] which warrant caution in reopening the economy on the basis of current vaccination rates. However, the cited studies are based on lumped age-structured compartmental or metapopulation models that can hardly capture the complexity and spatial structure of urban environments, along with details about behavioral traits of the population at the granularity of the single individual. Coarse-grained models smear the details that are captured by ABMs into a few macroscopic parameters, from which it is difficult to draw actionable decisions to steer interventions in the field.

When interpreting the results of our study, one needs to acknowledge several limitations of the model, the major one due to the resolution and quality of the available data — a common issue in the literature. For example, initial conditions on the health state of the town population are not directly available and were calibrated by rescaling available data at the county level. Likewise, the baseline values for the visits to leisure locations and private households prior to the reopening are educated guesses, based on publicly available local mobility data. Along with data limitations, we should acknowledge a range of simplifying assumptions that, within the philosophy of ABMs[39], are needed to reconcile computational complexity and model granularity with respect to public transport routes within the town, behavioral traits of the individuals, boundary conditions of the model, reopening efforts, and vaccine roll-out. For example, we set a uniform global parameter quantifying the reopening rate for all non-essential venues (leisure and house gatherings), without resolving one business versus another. Likewise, we assumed that vaccines have ideal efficacy, whereby a vaccinated agent becomes fully immune to COVID-19. This likely optimistic choice was dictated by the present uncertainty on the vaccine efficiency,

also in light of the uncertainty associated with new virus strains that are still under investigation. Last, we did not explicitly model contact tracing, although our ABM could be extended to faithfully reproduce real-world contact tracing practices, similar to those implemented by Reyna-Lara et al.[40] and Kojaku et al.[41]

As more people get vaccinated across the world, there is an understandable urge to reopen the economy. With arguments both in favor of and against accelerated return to normalcy reaching a high media pitch, it is critical that such debates be informed by scientifically grounded evidence. Our ABM offers a detailed representation of a mid-sized US town at the level of a single individual, which can support policy makers in assessing the cost/benefit ratios of reopening. The model is open source and accessible to researchers and practitioners across the World.

4. Experimental Section

The modeling framework consisted of two elements. The first was a detailed database of a US town, including its demographics, buildings and gathering locations, and mobility patterns of the population. The second was an ABM that emulates human mobility and behavior in the town, along with a location-specific epidemic transmission and progression model tailored to COVID-19. The model contemplated testing, isolation, treatment, and vaccination. In the following, the salient features of all the model components are detailed.

Database: The spatial layout of New Rochelle, NY was mapped by recording geographic coordinates and occupancy information of relevant locations, such as households, in-town and out-of-town workplaces, schools, retirement homes, hospitals, and leisure locations. Locations and capacities of in-town residential and public buildings, including schools, retirement homes, and the local hospital, were collected using OpenStreetMap[32] and Google Maps.[33] The locations and capacities of out-of-town workplaces and in-town leisure venues were gathered using SafeGraph[34]; leisure locations included a variety of stores, restaurants, arts, sports, and entertainment venues visited as part of a regular, off-work activity, see the Supporting Information for further details.

The synthetic ABM population comprised 79 205 agents and was generated to statistically match the age distribution from the most recent US Census data.[30] The number of agents assigned to households and residential buildings was exactly matched, and the number of residents in the retirement homes was estimated based on the size of such facilities. Students were assigned to schools using data from the National Center of Education Statistics.[42] The process of assigning agents to workplaces was informed by US Census data[30] about modes of transportation to work and travel times. Specifically, the distances from agents' households to their workplaces were estimated using US Census statistics on traveling times and transit modes. Then agents were statistically assigned to workplaces in or outside of the town by matching the distributions of such distances and of the number of employees within each workplace. At the onset of the simulation, the number of hospital patients was determined using data from the New York State Department of Health[43] and the American Hospital Directory.[44]

COVID-19 Progression Model: At each time-step, each agent could interact with other agents in the different locations they were assigned to (households, workplaces, schools, retirement homes, public transit, carpools, non-essential activities, and hospital). Agents could be susceptible to the disease, undergoing testing, under treatment, or vaccinated. It was also assumed that new agents do not enter during the simulation.

The progression model comprised six main states: susceptible (*S*), exposed—including asymptomatic individuals—(*E*), symptomatic (*Sy*), vaccinated (*V*), removed-healthy/recovered (*R*), and removed-dead (*D*). A detailed progression graph is illustrated in **Figure 4**. The exposed (*E*) state was attained by agents upon infection. When a latency period was over, exposed agents might develop symptoms and become symptomatic (*Sy*).



Figure 4. Schematic representation of modeled agent states and their possible transitions. Agent in the model could be in one of the following states: vaccinated (*V*); susceptible (*S*); exposed (*E*); symptomatic (*Sy*); removed-dead (*D*); removed-healthy/recovered (*R*). Agents in different states can undergo testing in a test car (T_C), or a hospital (T_{Hs}) after which they can be treated through home isolation (I_{Hm}), normal hospitalization (H_N), or hospitalization in an intensive care unit, ICU (H_{ICU}). In addition to symptomatic agents, exposed agents and agents who had COVID-19-like symptoms but were not COVID-19-infected (e.g., because of the flu) could be tested.

Symptomatic individuals were prevented from going to school and work, but they could freely move on public transportation and go to leisure locations or private households, for example to get basic necessities. Some exposed agents might recover without ever developing symptoms and transition to *R*.

Vaccinated agents (*V*) were assumed to be immune to COVID-19. At each time-step Δt, a constant fraction of the population ν, termed vaccination rate, randomly drawn from the susceptible agents (*S*) was vaccinated. These agents transitioned to state *V*. Susceptible, exposed, and symptomatic agents could undergo testing in a hospital (T_{Hs}) — carrying the possibility of infecting hospital staff and patients, or being infected if susceptible — or in drive-through facilities (T_C), which were assumed not to carry the risk of infection.[45] All the agents who were waiting to be tested or were waiting for the results of a test were home-isolated. Hence, they could not visit any location. The result of a test could be false or true positive, or false or true negative.

Agents who tested positive (either true or false) were subjected to three different treatment options: home isolation (I_{Hm}), normal hospitalization (H_N), and hospitalization in an intensive care unit, ICU (H_{ICU}). Exposed agents who tested positive were home-isolated until they became symptomatic. At that point, they could continue to be treated at home, or they could be hospitalized, changing their state to H_N or H_{ICU}. Symptomatic agents could undergo different treatment during the disease progression, eventually being removed from the model either as healthy/recovered (*R*) or dead (*D*). Removed agents did not contribute to the infection process. Untested symptomatic agents would not undergo any treatment, but they were eventually removed from the model, similar to the treated agents. However, untested agents who developed serious illness that would have required ICU had an increased probability of dying (*D*) with respect to those who received treatment.

This model also includes confounding factors at testing sites introduced by individuals with influenza-like symptoms, similar to COVID-19, who required testing.[46] The authors' relied on available data from Centers for Disease Control and Prevention (CDC) to introduce a constant number of such individuals in the population, rather than coupling a co-morbidity flu and cold model to our COVID-19 model. These individuals tended to increase the burden on testing sites, and they were exposed to a higher risk of infection from COVID-19 when visiting the testing site. Finally, they might increase the number of false positives upon COVID-19 testing. Such agents were still susceptible to COVID-19.

The ABM utilized a single parameter that captured the efficacy of testing practices without explicitly incorporating contact tracing practices at the individual level. This parameter determined the probability that an agent was tested, which was different depending on their health state (susceptible with influenza-like symptoms, exposed, and symptomatic agents). All the parameters that characterized the mechanisms described in the above are reported in the Supporting Information.

Human Mobility: An agent who took public transportation was assigned the route that was most suitable for their workplace location. Best routes for each possible destination were approximated using transit suggestions available from Google Maps.[33] The agents were grouped by routes, creating conditions for the disease spread. Carpools, on the other hand, were created only based on the workplace location and travel time of agents. Using the US Census data[30] on the number of passengers people commonly travel with, a realistic distribution of carpool capacities was maintained.

Agents who were not quarantined were allowed to perform non-essential activities, that is, to visit leisure locations or each other at their households. The same activity was imposed on all the agents in the same household. The assignment of a non-essential activity was executed for each time-step for a predetermined fraction of households $\phi_N(t)$, who was chosen according to the extent of the reopening efforts as

$$\phi_N(t) = \min\{\underline{\phi}_N + \rho(\overline{\phi}_N - \underline{\phi}_N)t, \overline{\phi}_N\} \tag{1}$$

where $\underline{\phi}_N$ and $\overline{\phi}_N$ are the minimum and maximum fraction of households that do non-essential activities, and ρ is the reopening rate, as detailed in the Supporting Information.

Households that were sampled to perform non-essential activities, were assigned either to a leisure location or to socially visit another household drawn uniformly at random. These two activities were assumed to be selected with equal probability. The leisure location itself was assigned by sampling a modified power-law distribution, shown to match mobility patterns of individuals, according to their cell phone records.[47] Specifically, at each time-step, each household that was part of the predetermined fraction was assigned a leisure location ℓ, $d_{i\ell}$ km away from their home, with a probability $q_{i\ell}$, such that

$$q_{i\ell} \propto \left(d_{i\ell} + d_{r0}\right)^{-\kappa_1} \exp\left(-\frac{d_{i\ell}}{\kappa_2}\right) \tag{2}$$

where $d_{r0} = 1.5$ km, $\kappa_1 = 1.75$, and $\kappa_2 = 400$ from Gonzalez et al.[47]

The current reopening rate in the town was estimated based on mobility data from Safegraph.[34] Specifically, data representing number of visits to individual points-of-interest by day, normalized, and smoothed with a 7-day window was extracted for the New York/New Jersey region for a period of 3 months starting from January 17, 2021. A straight line fit to this data revealed a reopening rate of 0.28% per day.

COVID-19 Transmission: A susceptible (S) agent i could become infected with COVID-19 (and thus exposed, E) at time t with the probability

$$p_i(t) := 1 - e^{-\Delta t \Lambda_i(t)} \tag{3}$$

where $\Delta t = 0.25$ day is the duration of a time-step and $\Lambda_i(t)$ reflects the infectiousness of all the locations that the agent is associated with. Specifically, $\Lambda_i(t)$ included contributions from different location types associated with agent i as,

$$\begin{aligned}\Lambda_i(t) :=& \lambda_{\mathrm{Hh},f_{\mathrm{Hh}}(i)}(t) + \lambda_{\mathrm{W},f_{\mathrm{W}}(i)}(t) + \lambda_{\mathrm{Sc},f_{\mathrm{Sc}}(i)}(t) + \lambda_{\mathrm{Rh},f_{\mathrm{Rh}}(i)}(t) \\ &+ \lambda_{\mathrm{Hsp},f_{\mathrm{Hsp}}(i)}(t) + \lambda_{\mathrm{Tr},f_{\mathrm{Tr}}(i)}(t) + \lambda_{\mathrm{N},f_{\mathrm{N}}(i,t)}(t)\end{aligned} \tag{4}$$

where $\lambda_{\bullet,\ell}(t)$ represents the infectiousness of location ℓ at time t (the first subscript is used to denote the type of location: Hh for households, W for workplaces, Sc for schools, Rh for retirement homes, Hsp for hospital, Tr for public transit and carpooling, and N for non-essential activity) and function $f_\bullet(i)$ selects the location type that agent i is assigned to. Note that the assignment of agents to non-essential activity was generally time-varying, since agents might visit different venues at different times.

The infectiousness of each in-town location (excluding non-essential activity) was proportional to the fraction of infectious agents (exposed and symptomatic individuals) at that location and to a characteristic transmission rate $\beta_\bullet$, which varied across the different types of locations, accounting for their varying risk. Precise expressions for the infectiousness of each type of location are reported in the Supporting Information. For out-of-town workplaces, infectiousness was assumed to be proportional to the estimated fraction of infected individuals in the neighboring US region[48–50] and to the transmission rate associated with workplaces, as detailed in the Supporting Information.

While the infectiousness at private gatherings was modeled using the household transmission rate (see Supporting Information), the infectiousness at a leisure location was proportional to the fraction of infectious individuals in that location and to the transmission rate associated with it. It was assumed that the transmission rate β_{L} was time-varying, increasing with reopening efforts. Specifically, the full-capacity transmission rate of leisure locations, $\overline{\beta}_{\mathrm{L}}$, was set using data on average secondary-attack-rates from real-life COVID-19 outbreaks reported by Koh et al.[51] Then, the initial transmission rate was set as 57% of such a quantity, that is, $\underline{\beta}_{\mathrm{L}} = 0.57\overline{\beta}_{\mathrm{L}}$, based on Google Mobility Reports.[52] Hence, the transmission rate in leisure locations would at the reopening rate ρ according to

$$\beta_{\mathrm{L}}(t) = \min\{\underline{\beta}_{\mathrm{L}} + \rho(\overline{\beta}_{\mathrm{L}} - \underline{\beta}_{\mathrm{L}})t, \overline{\beta}_{\mathrm{L}}\} \tag{5}$$

where $t = 0$ is the start of the simulation, details can be found in the Supporting Information.

Model Calibration: The backbone of the ABM was based on the work of Truszkowska et al.,[28] where calibration was performed on the officially reported data on the COVID-19 epidemic in New Rochelle, NY during the first wave of COVID-19 (March through July of 2020).[53] The calibration parameters were limited to only eight unknown variables, namely, number of initially infected agents, time-varying fraction of exposed and symptomatic agents who were tested, transmission reductions associated with the lockdown and three local reopening phases, and age-distribution of asymptomatic agents. All other model parameters obtained from established sources, including clinical data on COVID-19. Through this effort, a base parameter set that was identified allowed to closely replicate the evolution of the first wave of COVID-19 in the town. Specifically, the total number of detected cases, the number of new cases confirmed every week, the weekly average of individuals treated for COVID-19, and the number of casualties reported each week were matched.

Aiming to achieve conditions as close as possible to the current ones, the original set of parameters was updated with more recent data and estimates on closures and testing practices. To acknowledge the fact that businesses are now open but not operating at full capacity, the infection risk in all the general workplaces were scaled down using the Google COVID-19 Mobility Report for Westchester county.[52] Likewise, since schools are now operating in a hybrid mode,[54] transmission rates are reduced accordingly. The complete list of parameters and their sources are available in the Supporting Information.

Different testing levels for simulating the different scenarios were implemented by increasing the probability of testing for an asymptomatic and symptomatic agent during the simulation. For example, for perfect testing all asymptomatic and symptomatic agents were tested, whereas for low testing a symptomatic agent was tested with a probability of 0.64 and an asymptomatic agent was tested with a probability of 0.44.

Supporting Information

Supporting Information is available from the Wiley Online Library or from the author.

Acknowledgements

This work was partially supported by National Science Foundation (CMMI-1561134, CMMI-2027990, and CMMI-2027988) and by Compagnia di San Paolo.

Conflict of Interest

The authors declare no conflict of interest.

Author Contributions

Conceptualization—A.T., S.B., Z.P.J., A.R., and M.P.; methodology—A.T. and S.B.; software—A.T. and S.B.; validation—A.T.; investigation—all the authors; resources—M.P.; data curation—A.T. and M.T.; writing—original draft preparation—A.T., L.Z., S.B., A.R., and M.P.; writing—review and editing—M.T., E.C., and Z.P.J.; visualization—A.T.; supervision—S.B., E.C., Z.P.J., A.R., and M.P.; project administration—M.P.; funding acquisition—S.B., Z.P.J., A.R., and M.P.

Data Availability Statement

The data that support the findings of this study are openly available in Github at https://github.com/Dynamical-Systems-Laboratory/NR-population-mobility. The code used in this paper is openly available in Github at https://github.com/Dynamical-Systems-Laboratory/ABM-COVID-Mobility.

Keywords

agent-based model, COVID-19, epidemiology, urban science, vaccination

Received: May 4, 2021
Revised: June 19, 2021
Published online: August 1, 2021

[1] Our World in Data, Coronavirus (COVID-19) Vaccinations, https://ourworldindata.org/covid-vaccinations (accessed: June 2021).
[2] Forbes, https://www.forbes.com/advisor/personal-finance/americans-still-split-about-reopening-economy (accessed: June 2021).
[3] Pew Research, A year of U.S. public opinion on the coronavirus pandemic, https://www.pewresearch.org/2021/03/05/a-year-of-u-s-public-opinion-on-the-coronavirus-pandemic (accessed: June 2021).
[4] New York Times, New York's reopening is 'wild,' 'hopeful,' 'exciting,' and 'bad', https://www.nytimes.com/2021/03/25/opinion/new-york-reopening-bars.html (accessed: June 2021).
[5] E. Estrada, *Phys. Rep.* **2020**, *869*, 1.
[6] A. Vespignani, H. Tian, C. Dye, J. O. Lloyd-Smith, R. M. Eggo, M. Shrestha, S. V. Scarpino, B. Gutierrez, M. U. G. Kraemer, J. Wu, K. Leung, G. M. Leung, *Nat. Rev. Phys* **2020**, *2*, 279.
[7] A. L. Bertozzi, E. Franco, G. Mohler, M. B. Short, D. Sledge, *Proc. Natl. Acad. Sci. USA* **2020**, *117*, 16732.
[8] N. Perra, *Phys. Rep.* **2021**, *913*, 1.
[9] F. Della Rossa, D. Salzano, A. Di Meglio, F. De Lellis, M. Coraggio, C. Calabrese, A. Guarino, R. Cardona-Rivera, P. De Lellis, D. Liuzza, F. Lo Iudice, G. Russo, M. di Bernardo, *Nat. Commun.* **2020**, *11*, 5106.
[10] F. Pinotti, L. Di Domenico, E. Ortega, M. Mancastroppa, G. Pullano, E. Valdano, P.-Y. Boëlle, C. Poletto, V. Colizza, *PLOS Med.* **2020**, *17*, e1003193.
[11] A. Arenas, W. Cota, J. Gómez-Gardeñes, S. Gómez, C. Granell, J. T. Matamalas, D. Soriano-Paños, B. Steinegger, *Phys. Rev. X* **2020**, *10*, 041055.
[12] F. Parino, L. Zino, M. Porfiri, A. Rizzo, *J. R. Soc., Interface* **2021**, *18*, 20200875.
[13] K. H. Cheong, T. Wen, J. W. Lai, *Adv. Sci.* **2020**, *7*, 2002324.
[14] U. Goldsztejn, D. Schwartzman, A. Nehorai, *PLOS One* **2020**, *15*, 1.
[15] H. Noorbhai, *Ann. Med. Surg.* **2020**, *57*, 5.
[16] K. M. Bubar, K. Reinholt, S. M. Kissler, M. Lipsitch, S. Cobey, Y. H. Grad, D. B. Larremore, *Science* **2021**, *371*, 916.
[17] P. C. Jentsch, M. Anand, C. T. Bauch, *Lancet Infect. Dis.* **2021**, https://doi.org/10.1016/S1473-3099(21)00074-8.
[18] M. Shen, J. Zu, C. K. Fairley, J. A. Pagán, L. An, Z. Du, Y. Guo, L. Rong, Y. Xiao, G. Zhuang, Y. Li, L. Zhang, *Vaccine* **2021**, *39*, 2295.
[19] G. Giordano, M. Colaneri, A. D. Filippo, F. Blanchini, P. Bolzern, G. D. Nicolao, P. Sacchi, R. Bruno, P. Colaneri, *Nat. Med.* **2021**, *27*, 993.
[20] S. Moore, E. M. Hill, M. J. Tildesley, L. Dyson, M. J. Keeling, *Lancet Infect. Dis.* **2021**, *21*, 793.
[21] S. Grundel, S. Heyder, T. Hotz, T. K. S. Ritschel, P. Sauerteig, K. Worthmann, *medRxiv*, **2020**, https://doi.org/10.1101/2020.12.22.20248707.
[22] M. Galanti, S. Pei, T. K. Yamana, F. J. Angulo, A. Charos, D. L. Swerdlow, J. Shaman, *medRxiv*, **2020**, https://doi.org/10.1101/2020.12.23.20248784.
[23] N. Agarwal, A. Komo, C. A. Patel, P. A. Pathak, U. Unver, *EconPapers*, **2021**, https://EconPapers.repec.org/RePEc:nbr:nberwo:28519.
[24] A. N. Kraay, M. E. Gallagher, Y. Ge, P. Han, J. M. Baker, K. Koelle, A. Handel, B. A. Lopman, *medRxiv*, **2021**, https://doi.org/10.1101/2021.03.12.21253481.
[25] N. M. Ferguson, D. Laydon, G. Nedjati-Gilani, N. Imai, K. Ainslie, S. B. Marc Baguelin, A. Boonyasiri, Z. Cucunubá, G. Cuomo-Dannenburg, A. Dighe, I. Dorigatti, H. Fu, K. Gaythorpe, W. Green, A. Hamlet, W. Hinsley, L. C. Okell, S. van Elsland, H. Thompson, R. Verity, E. Volz, H. Wang, Y. Wang, C. W. Patrick, G. T. Walker, P. Winskill, C. Whittaker, C. A. Donnelly, S. Riley, A. C. Ghani, Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand, Report of the Imperial College London, UK https://doi.org/10.25561/77482, (accessed: June 2021).
[26] M. Chinazzi, J. T. Davis, M. Ajelli, C. Gioannini, M. Litvinova, S. Merler, A. P. y Piontti, K. Mu, L. Rossi, K. Sun, C. Viboud, X. Xiong, H. Yu, M. E. Halloran, I. M. Longini, A. Vespignani, *Science* **2020**, *368*, 395.
[27] N. Hoertel, M. Blachier, C. Blanco, M. Olfson, M. Massetti, M. S. Rico, F. Limosin, H. Leleu, *Nat. Med.* **2020**, *26*, 1417.
[28] A. Truszkowska, B. Behring, J. Hasanyan, L. Zino, S. Butail, E. Caroppo, Z.-P. Jiang, A. Rizzo, M. Porfiri, *Adv. Theory Simul.* **2021**, *4*, 2170005.
[29] CNN News, New York officials traced more than 50 coronavirus cases back to one attorney, https://www.cnn.com/2020/03/11/us/new-rochelle-attorney-containment-area/index.html (accessed: June 2021).
[30] United States Census Bureau, Explore Census Data, https://data.census.gov/cedsci (accessed: June 2021).
[31] United States Census Bureau, America: A Nation of Small Towns, https://www.census.gov/library/stories/2020/05/america-a-nation-of-small-towns.html (accessed: June 2021).
[32] OpenStreetMap Community, Openstreetmap, https://www.openstreetmap.org (accessed: June 2021).
[33] Google, Google Maps, https://www.google.com/maps (accessed: June 2021).
[34] SafeGraph Inc., SafeGraph, https://www.safegraph.com (accessed: June 2021).
[35] G. Young, P. Xiao, K. Newcomb, E. Michael, *arXiv*, **2021**, https://arxiv.org/abs/2103.06120.

[36] Healthline, Vaccinated or Not, COVID-19 Testing is Still Important, Here's Why?, https://www.healthline.com/health-news/vaccinated-or-not-covid-19-testing-is-still-important-heres-why#Fewer-cases,-less-testing (accessed: June 2021).
[37] Scientific American, Safely Reopening Requires Testing, Tracing and Isolation, Not Just Vaccines, https://www.scientificamerican.com/article/safely-reopening-requires-testing-tracing-and-isolation-not-just-vaccines (accessed: June 2021).
[38] UK Government, New Campaign Urges Public to get tested twice a week, https://www.gov.uk/government/news/new-campaign-urges-public-to-get-tested-twice-a-week (accessed: June 2021).
[39] A. Pastore y Piontti, N. Perra, L. Rossi, N. Samay, A. Vespignani, *Charting the Next Pandemic*, Springer International Publishing, Cham, Switzerland **2019**.
[40] A. Reyna-Lara, D. Soriano-Paños, S. Gómez, C. Granell, J. T. Matamalas, B. Steinegger, A. Arenas, J. Gómez-Gardeñes, *Phys. Rev. Res.* **2021**, *3*, 013163.
[41] S. Kojaku, L. Hébert-Dufresne, E. Mones, S. Lehmann, Y.-Y. Ahn, *Nat. Phys.* **2021**, *17*, 652.
[42] Institute for Education Science, National Center for Education Statistics, https://nces.ed.gov (accessed: June 2021).
[43] New York State Department of Health, NYS Health Profiles — Montefiore New Rochelle Hospital, https://profiles.health.ny.gov/hospital/view/103001 (accessed: June 2021).
[44] American Hospital Directory, Montefiore New Rochelle Hospital, https://www.ahd.com/free_profile/330184/Montefiore_New_Rochelle_Hospital/New_Rochelle/New_York (accessed: June 2021).
[45] A. Shah, D. Challener, A. J. Tande, M. Mahmood, J. C. O'Horo, E. Berbari, S. J. Crane, *Mayo Clin. Proc.* **2020**, *95*, 1420.
[46] Centers for Disease Control and Prevention, Similarities and differences between flu and COVID-19, https://www.cdc.gov/flu/symptoms/flu-vs-covid19.html (accessed: June 2021).
[47] M. C. Gonzalez, C. A. Hidalgo, A.-L. Barabasi, *Nature* **2008**, *453*, 779.
[48] COVID-19 Forecast Hub, COVID-19 Connecticut weekly forecast summary, https://covid19forecasthub.org/reports/single_page.html?state=CT&week=2021-03-30#County_level, (Accessed: June 2021).
[49] COVID-19 Forecast Hub, COVID-19 New York Weekly Forecast Summary, https://covid19forecasthub.org/reports/single_page.html?state=NY&week=2021-03-30#County_level (accessed: June 2021).
[50] United States Census Bureau, QuickFacts, Westchester County, New York; United States, https://www.census.gov/quickfacts/fact/table/westchestercountynewyork,US/PST045219 (accessed: June 2021).
[51] W. C. Koh, L. Naing, L. Chaw, M. A. Rosledzana, M. F. Alikhan, S. A. Jamaludin, F. Amin, A. Omar, A. Shazli, M. Griffith, R. Pastore, J. Wong, *PLOS One* **2020**, *15*, e0240205.
[52] Google, COVID-19 Community Mobility Report for New York State Counties, https://www.gstatic.com/covid19/mobility/2021-03-31_US_New_York_Mobility_Report_en.pdf (accessed: June 2021).
[53] Westchester County, Westchester County official Twitter Account, https://twitter.com/westchestergov, 2021.
[54] City School District of New Rochelle, COVID Resource Center, https://www.nred.org/covid_resource_center#gsc.tab=0 (accessed: June 2021).